ClearPoint Neuro, Inc. filings document the company's medical-device and therapy-enabling business, including operating results for its brain and spine navigation platforms, CNS drug-delivery services, and neurocritical-care portfolio after the completed IRRAS Holdings acquisition. Form 8-K reports furnish quarterly and annual results, Regulation FD investor presentations, acquisition-related financial statements, pro forma combined financial information, and material-event disclosures.
Proxy materials cover governance matters, director voting, executive compensation, pay-versus-performance data, and equity-award disclosures. The filing record also includes material agreements, capital-structure disclosure, shareholder voting matters, and clinical or regulatory disclosures tied to the company's regulated neurosurgical products and partnered biologics programs.
CLPT filed a Rule 144 notice reporting securities to be sold through Morgan Stanley Smith Barney LLC. The filing lists 9,156 previously vested restricted stock awards and 12,638 previously vested restricted stock units as securities to be sold.
The filing also discloses recent 10b5-1 sales, including a 20,000 share sale on 01/09/2026 for $322,404.00 and a 2,943 share sale on 01/26/2026 for $45,813.39.
CLPT submitted an amendment to a Form 144/A reporting resale activity in Common stock, including a 10b5-1 sale of 26,463 shares on 10/10/2025 for $714,032.60. The amendment lists prior and planned issuer awards under employee plans with dated grant entries.
ClearPoint Neuro, Inc. reported that Chief Operating Officer Sabra Mazin acquired 36,818 restricted stock units (RSUs) of company stock as a compensation award. Each RSU represents a contingent right to receive one share of CLPT common stock if vesting conditions are met.
The award vests over three years: 20% of the RSUs on February 17, 2027, 40% on February 17, 2028, and the remaining 40% on February 17, 2029. After this grant, Mazin directly holds 36,818 RSUs, aligning part of her compensation with the company’s future performance.
STIGALL L. JEREMY reported acquisition or exercise transactions in this Form 4 filing.
ClearPoint Neuro, Inc. Chief Business Officer L. Jeremy Stigall received a grant of 51,546 restricted stock units of ClearPoint Neuro common stock. Each unit represents the right to receive one share of CLPT common stock at vesting. The award vests over three years: 20% of the units on February 17, 2027, 40% on February 17, 2028, and the remaining 40% on February 17, 2029, aligning a substantial portion of his compensation with the company’s long-term performance.
D'Alessandro Danilo reported acquisition or exercise transactions in this Form 4 filing.
ClearPoint Neuro, Inc. reported that Chief Financial Officer Danilo D'Alessandro received a grant of 66,273 restricted stock units. Each unit represents a contingent right to one share of CLPT common stock. The units vest 20% on February 17, 2027, 40% on February 17, 2028, and 40% on February 17, 2029.
ClearPoint Neuro, Inc. reported that CEO and President Joseph Burnett acquired a grant of 147,275 restricted stock units. Each unit represents a contingent right to receive one share of CLPT common stock.
The restricted stock units vest over three years: 20% of the total shares on February 17, 2027, 40% on February 17, 2028, and the remaining 40% on February 17, 2029, aligning the award with multi-year executive retention and performance incentives.
ClearPoint Neuro filed an amended current report to add detailed financial information for its acquisition of IRRAS Holdings, Inc. The 8-K/A supplies IRRAS’s audited 2024 financial statements, unaudited 2025 interim results, and unaudited pro forma combined financials showing how the two businesses would look if reported together.
The company emphasizes that these pro forma figures are for informational purposes only and do not represent actual historical results or forecasts of future performance after the acquisition.
Bigger Capital Fund LP and related entities filed an amended Schedule 13G reporting their beneficial ownership of ClearPoint Neuro, Inc. common stock as of February 4, 2026. Bigger Capital and its general partner Bigger Capital Fund GP, LLC report beneficial ownership of 1,333,155 shares, or about 4.69% of the outstanding stock.
District 2 Capital Fund LP and its affiliated entities report beneficial ownership of 337,696 shares, or about 1.19%. Michael Bigger may be deemed to beneficially own about 7.8% of the common stock, including interests attributed through these funds and family holdings. The percentages are based on 28,423,308 shares outstanding as of October 27, 2025, and the filers certify the holdings are not for the purpose of changing or influencing control of ClearPoint Neuro.
ClearPoint Neuro, Inc. insider activity: a trust associated with CEO and President Joseph Burnett sold 2,943 shares of ClearPoint Neuro common stock on 01/26/2026 at a weighted average price of $15.57 per share, under a pre-arranged Rule 10b5-1 trading plan adopted on June 11, 2025.
After this sale, the Joseph M. Burnett Trust held 214,116 shares indirectly for Mr. Burnett, and he also held 11,565 shares directly. The sale price range was from $15.23 to $15.65 per share, and detailed trade breakdowns are available from the company or the SEC staff upon request.
A holder of CLPT common stock filed a notice to sell 2,943 shares under Rule 144. The shares are common stock to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services, with an aggregate market value of $46,146.24, and an approximate sale date of 01/26/2026 on the NASDAQ market. These 2,943 shares were acquired on 08/20/2023 as restricted stock units from the issuer, matching the amount now planned for sale. The filing notes that a related 10b5-1 plan already led to a prior sale of 20,000 common shares on 01/09/2026 for $322,404 in gross proceeds, and states that total common shares outstanding are 28,423,308.